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Samata Tiwari, Shaila Siddiqi, and Shadab A. Siddiqi1
From the Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827
Background: Nascent VLDL exits the ER in a specialized large vesicle, the VTV.
Results: CideB interacts with COPII proteins, and CideB ablation abrogates VTV biogenesis.
Conclusion: CideB forms an intricate COPII coat and regulates the formation of the VTV.
Significance: New physiological role of CideB provides new insight into the mechanism that controls intracellular VLDL
trafficking and secretion.

Intracellular transport of newly synthesized lipoproteins
from the ER2 to the Golgi is of utmost importance because
abnormalities associated with this transport step lead to the
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analysis of variance.
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pathogenesis of various metabolic diseases (1, 2). The liver and
the small intestine are two organs that primarily produce lipoproteins: VLDL and chylomicrons, respectively. In liver, the
biogenesis of VLDLs occurs in the ER, and this process is facilitated by microsomal triglyceride transfer protein (3–9). Once
synthesized in the ER lumen, nascent VLDLs are exported to
the Golgi, where several essential modifications occur to VLDL
particles (10 –14). Their structural protein, apolipoprotein
B100 (apoB100), gets further glycosylated and phosphorylated
(12–14). Moreover, it has been proposed that additional triglycerides are added to the nascent VLDL in the Golgi lumen
(11, 15–17). Based on a number of biochemical and histological
data, it has been suggested that Golgi is the site of VLDL maturation; however, this supposition is still a subject of debate
(11–20). Regardless of their maturation site, the transport of
nascent VLDL particles from the ER to the Golgi is imperative
and determines the rate of VLDL secretion from the liver (10).
Transport of nascent VLDL from the ER is mediated by a
specialized vesicle, the VTV, which buds off the hepatic ER
membranes (21). Although these vesicles have been shown to
be morphologically and biochemically different from classical
ER-derived PTVs, their biogenesis requires COPII proteins
(22–28). COPII proteins consist of five cytosolic proteins Sar1,
Sec23-Sec24, and Sec13-Sec31 (29, 30). These five proteins
have been shown to be sufficient to select cargo proteins and
facilitate vesicle formation from the ER membrane. Sar1, a
COPII component that initiates vesicle biogenesis, has two
mammalian homologs: Sar1a and Sar1b (31). Several studies
have shown that Sar1b is involved in lipoprotein trafficking and
secretion because mutations in Sar1b lead to chylomicron
retention disease (32–36). The definitive role of Sar1 in VLDL
exit from the hepatic ER has been evident from our data and
those of others (15, 21). Using H89, an inhibitor of Sar1 recruitment to the ER membrane, we found a significant reduction in
VTV formation (21). Overexpression of dominant negative
Sar1 (Sar1T39N) in rat hepatoma cells significantly blocks ERto-Golgi transport of apoB100, a core component of VLDL (15).
That both nascent VLDL and secretory proteins exit the
same ER in two different kinds of vesicles that require the same
initiator for their genesis, Sar1, and other COPII components,
has been shown in many studies (15, 21). These observations,
however, raise the possibility of potential involvement of an
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Nascent very low density lipoprotein (VLDL) exits the endoplasmic reticulum (ER) in a specialized ER-derived vesicle, the
VLDL transport vesicle (VTV). Similar to protein transport vesicles (PTVs), VTVs require coat complex II (COPII) proteins for
their biogenesis from the ER membranes. Because the size of the
VTV is large, we hypothesized that protein(s) in addition to
COPII components might be required for VTV biogenesis. Our
proteomic analysis, supported by Western blotting data, shows
that a 26-kDa protein, CideB, is present in the VTV but not in
other ER-derived vesicles such as PTV and pre-chylomicron
transport vesicle. Western blotting and immunoelectron
microscopy analyses suggest that CideB is concentrated in the
VTV. Our co-immunoprecipitation data revealed that CideB
specifically interacts with VLDL structural protein, apolipoprotein B100 (apoB100), but not with albumin, a PTV cargo protein.
Confocal microscopic data indicate that CideB co-localizes with
apoB100 in the ER. Additionally, CideB interacts with COPII
components, Sar1 and Sec24. To investigate the role of CideB in
VTV biogenesis, we performed an in vitro ER budding assay. We
show that the blocking of CideB inhibits VTV budding, indicating a direct requirement of CideB in VTV formation. To confirm
our findings, we knocked down CideB in primary hepatocytes
and isolated ER and cytosol to examine whether they support
VTV budding. Our data suggest that CideB knockdown significantly reduces VTV biogenesis. These findings suggest that
CideB forms an intricate COPII coat and regulates the VTV
biogenesis.

VTV Formation Requires CideB

EXPERIMENTAL PROCEDURES
Reagents—[3H]Oleic acid (45.5 Ci/mM) was obtained from
PerkinElmer Life Sciences. Reagents used for immunoblotting
were purchased from Bio-Rad. ECL (enhanced chemiluminescence) reagents were purchased from GE Healthcare. Protease
inhibitor mixture tablets were obtained from Roche Applied
Science. Albumin was purchased from Sigma. Other biochemical reagents used were of analytical grade and were purchased
from local companies. Sprague-Dawley rats, 150 –200 g, were
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obtained from Harlan Laboratories (Indianapolis, IN). All procedures involving animals were conducted according to the
guidelines of the University of Central Florida Institutional
Animal Care and Use Committee (IACUC) and strictly following the IACUC approved protocol.
Antibodies—Goat polyclonal antibodies to CideB, calnexin,
Ykt6, and GOS28; rabbit polyclonal antibodies to syntaxin 5,
Sec13, Sec23, Sec31, and Sec24; and goat anti-rabbit IgG Texas
Red and bovine anti-goat IgG-fluorescein isothiocyanate-conjugated antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rabbit polyclonal anti-Sar1 antibodies were generated commercially and have been described
previously (21). Rabbit polyclonal antibodies against rat
VAMP7 (vesicle-associated membrane protein 7; amino acids
105–123) were described earlier (53). Mouse monoclonal antibodies to rBet1 and membrin were procured from StressGen
(Vancouver, Canada). Rabbit anti-rat albumin antibody was
purchased from Bethyl Laboratories, Inc. (Montgomery, TX),
and rabbit polyclonal anti-apoB antibodies were a gift from Dr.
Larry Swift (Department of Pathology, Vanderbilt University,
Nashville, TN). Rabbit anti-goat IgG and goat anti-rabbit IgG
conjugated with agarose beads were purchased from Sigma.
Primary Hepatocyte Culture—Primary hepatocytes were isolated from adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN). Hepatocytes were isolated using collagen perfusion as described previously (54, 55). Briefly, liver was
perfused with Krebs buffer (121 mM NaCl, 25 mM NaHCO3, 4.8
mM KCl, 2 mM MgSO4, and 1.2 mM KH2PO4; pH 7.2). This was
followed by perfusion with type II collagenase (Worthington
Biochemical Corp.). Cell suspension was obtained in RPMI
1640 (Life Technologies), supplemented with 1 M dexamethasone (Sigma), 100 nM insulin (Sigma), 5% FBS (Life Technologies), 1% penicillin streptomycin (Sigma). Cells were seeded on
a 60-mm collagen-coated dish (BD Biosciences) with the density of 3 ⫻ 106 cells/plate. After 4 h, unattached cells were
removed, and fresh medium was added followed by overnight
incubation.
Preparation of Radiolabeled Hepatic ER and cis- and
trans-Golgi—ER labeled with [3H]triacylglycerol (TAG) was
prepared from rat liver using the same method as we have
described previously (21). Briefly, primary hepatocytes in buffer
B (136 mM NaCl, 11.6 mM KH2PO4, 8 mM Na2HPO4, 7.5 mM
KCl, 0.5 mM dithiothreitol; pH 7.2) were incubated with BSAbound [3H]oleate (100 Ci) for 35 min at 37 °C and washed
twice with 2% BSA in PBS to wash the excess of [3H]oleate. Cells
were then homogenized in 0.25 M sucrose in 10 mM Hepes, 50
mM EDTA, and protease inhibitor (Roche Diagnostics GmbH,
Mannheim, Germany) in a Parr bomb at 1,100 psi for 40 min
followed by isolation of ER and cis- and trans-Golgi in a sucrose
step gradient (21, 42, 56).
Preparation of Hepatic Cytosol—Hepatic cytosol was prepared by following the same method as described previously
(21). After washing with Krebs buffer, cells were washed in
cytosol buffer (25 mM Hepes, 125 mM KCl, 2.5 mM MgCl2, 0.5
mM DTT, and protease inhibitors; pH 7.2) and homogenized
using a Parr bomb at 1,100 psi for 40 min. This was followed by
centrifugation at 40,000 rpm for 95 min (Beckman rotor 70.1
Ti). Supernatant was dialyzed overnight against ice-cold fresh
VOLUME 288 • NUMBER 7 • FEBRUARY 15, 2013
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additional factor(s) that is required for either cargo selection or
vesicle biogenesis. It has been demonstrated that several cargoes require additional cytosolic proteins for their exit from the
ER (37– 46). For example, the formation of pre-chylomicron
transport vesicle (PCTV) from the intestinal ER requires four
cytosolic proteins in addition to five COPII proteins (43). These
nine proteins form a prebudding complex that leads to the formation of the PCTVs, which contain pre-chylomicrons and are
able to fuse with and deliver their cargo to the Golgi lumen (43,
44). It is possible that the generation of PCTV requires extra
proteins because of its very large size and that these additional
proteins facilitate the formation of a larger cage. However, the
requirement of protein(s) other than COPII is not limited to
larger cargoes or their carrier vesicles; smaller cargoes such as
amyloid precursor protein need additional cytosolic factor(s)
for their exit from the ER (47). These findings suggest that proteins other than COPII are required either for sorting and packaging of specific cargoes into vesicles or for the genesis of specialized vesicles that transport specific cargoes to the Golgi.
Because the size of the VTV (100 –120 nm) is larger than the
size of a normal COPII vesicle (⬃55–70 nm), it is likely that
generation of the VTV requires supplementary protein(s). We
recently carried out a detailed proteomic analysis of the VTV to
find out proteins present exclusively in VTV (48). Of several
important proteins, which are not present in other ER-derived
vesicles such as PCTV and PTV, one protein was identified as
CideB (cell death-inducing DFF45-like effector b) (48). Interestingly, CideB has been shown to be involved in secretion of
VLDL (49, 50). CideB belongs to the CIDE family, which
includes CideA, CideB, and CideC, also called as Fsp27 in mice,
and these proteins are reported to play important roles in lipoprotein metabolism (51). CideB is expressed in liver and kidney
and is associated with maturation and secretion of VLDL and
apoptosis (51, 52). It has been reported that CideB⫺/⫺ mice
have reduced secretion of VLDL particles, which are also small
in size (49). However, the presence of CideB or its functional
role in VTV biogenesis has not been investigated so far.
In the current study, we sought to identify the role of CideB
in VTV budding. We found that CideB interacts with apoB100
in the ER, whereas it does not interact with albumin, which is
excluded from the VTV. Our data suggest that CideB interacts
with Sar1 at the ER level. The interaction of CideB with VLDL
cargo protein, apoB100, and COPII component, Sar1, indicates
its role in VTV biogenesis and thus VLDL exit from the ER. We
further examined the effect of blocking the function of CideB or
CideB knockdown on VTV generation from the ER. We report
that CideB forms a specialized complex with COPII proteins
that leads to the biogenesis of the VTV.

VTV Formation Requires CideB
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Biosciences). Cells were washed three times with PBS, fixed
with 4% paraformaldehyde (Electron Microscopy Sciences,
Hatfield, PA) for 10 min, and permeabilized with 0.2% Triton
X-100 (Fisher Scientific) for 10 min at room temperature. After
washing three times with PBS, cells were blocked with 5% BSA
solution in PBS for 30 min at room temperature. Cells were
then double-labeled with goat anti-CideB (1:100) and either
rabbit anti-apoB100 (1:100) or rabbit anti-calnexin antibodies
(1:100) for 1 h at room temperature and washed three times
with PBS. Next, cells were incubated in dark with species-specific secondary antibody, bovine anti-goat IgG-FITC (1:500),
and goat anti-rabbit IgG-Texas Red (1:500) for 45 min at room
temperature. After washing with PBS, cells were mounted on a
glass slide using mounting medium (Electron Microscopy Sciences, Hatfield, PA) and visualized using the Zeiss spinning disk
confocal microscope and velocity image analyzer software.
Immunoelectron Microscopy—In an attempt to examine the
localization of CideB on VTVs by immunoelectron microscopy,
we adopted the negative staining approach and followed the
same methodology for immunogold labeling of the VTVs as
described previously (46, 48, 56). In brief, VTVs adsorbed on
Formvar/carbon-coated nickel grids were incubated with 10%
(w/v) BSA containing either anti-rabbit preimmune IgG (1:100)
or rabbit polyclonal anti-CideB antibodies (1:100) for 4 h. Samples were washed with PBS and incubated with anti-rabbit IgG
(1:50) conjugated with 15-nm colloidal gold. After washing
with PBS, samples were subsequently fixed in 1% (w/v) glutaraldehyde in PBS for 10 min, stained with 0.5% aqueous uranyl
acetate for 1 min, and examined at 12,000⫻ magnification.
Statistical Analysis—Data were compared using a one-way
analysis of variance (ANOVA) using GraphPad software
(GraphPad Prism 5 Software for Mac OS X version).

RESULTS
CideB Is Present in the Hepatic ER, Golgi, Cytosol, and VTV—
Our first goal was to determine the distribution of CideB in
various subcellular organelles in primary hepatocytes. To
achieve this, we separated the ER, Golgi, and cytosol from primary hepatocytes. Because the purity of subcellular fractions
isolated from primary hepatocytes is considered crucial for the
success of our in vitro assays, we carried out Western blotting
utilizing organelle-specific protein markers for ER and Golgi to
establish their purity as reported previously (21, 56). Our results
show that ER did not contain recognizable GOS28, a Golgi
marker protein, whereas Golgi was free from calnexin, an ER
marker protein (Fig. 1A). Both ER and Golgi membranes were
found to be devoid of Rab11, an endosomal/lysosomal marker
protein (data not shown). After confirming that our subcellular
organelles are of adequate purity, we performed a pre-established in vitro VTV budding assay to prepare VTVs, which were
purified and characterized as we reported earlier (21). To make
sure that our vesicular fraction contains bona fide VTVs, we
probed for VTV markers, Sar1 and apoB100. As shown in Fig.
1A, both proteins were concentrated in VTV fractions, suggesting that we have adequate VTV fractions to perform further
analysis. To examine that CideB is present in the VTV, ER,
Golgi, and cytosol, we performed Western blotting using specific CideB antibodies. The data presented in Fig. 1A show that
JOURNAL OF BIOLOGICAL CHEMISTRY
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cytosol buffer and concentrated using a Centricon filter (Amicon, Beverly, MA) and ultrafiltration membrane (Millipore, Billerica, MA) with a cut-off of 10 kDa to a final concentration of
protein to 17 mg/ml.
In Vitro VTV Formation—The in vitro VTV formation was
carried out as established previously in our laboratory (21, 48,
56). In brief, ER having [3H]TAG (500 g) was incubated at 37
°C for 30 min with hepatic cytosol (1 mg of protein), an ATPregenerating system, 5 mM Mg2⫹, 5 mM Ca2⫹, 5 mM DTT, 1 mM
GTP, 1 mM E600. Reaction mixture volume was adjusted to 500
l by the addition of transport buffer (30 mM Hepes, 250 mM
sucrose, 2.5 mM MgOAc, 30 mM KCl; pH 7.2). Next, the reaction mixture was placed on a sucrose continuous gradient made
from 0.2 and 2.1 M sucrose, respectively, and centrifuged using
a Beckman rotor SW41 at 25,900 rpm for 2 h at 4 °C, resulting in
resolution of VTV in lighter fractions. Fractions (500 l) having
VTV were separated from sucrose continuous gradient.
Measurement of Radioactivity—Radioactivity associated
with [3H]TAG was measured in terms of dpm by using a TriCarb 2910TR liquid scintillation analyzer (PerkinElmer Life
Sciences) (21, 42).
Co-immunoprecipitation—ER membranes (250 g) were
solubilized in ice-cold PBS containing 2% (v/v) Triton X-100
(Fisher Scientific) at 4 °C for 15 min. Next, rabbit anti-apoB100
antibodies were added and incubated for 4 h at 4 °C. Similarly,
parallel experiments were performed with goat anti-CideB and
rabbit anti-albumin. After 4 h, either anti-goat or anti-rabbit
IgGs bound to agarose beads were added and incubated overnight at 4 °C. Beads bound to immunocomplexes were washed
12 times with ice-cold PBS (21, 43).
Preparation of Cell Extract—Rat hepatocytes were lysed
using radioimmunoprecipitation assay buffer (Thermo Scientific) supplemented with protease inhibitor. Lysed cell extract
was centrifuged at 13,000 ⫻ g for 15 min. Supernatant obtained
was used to determine protein concentration.
SDS-PAGE and Immunoblot Analysis—Concentration of
protein in ER and whole cell lysate was determined by the Bradford method (21). Protein samples were separated by SDSPAGE followed by transblotting onto a nitrocellulose membrane (Bio-Rad). Detection of protein was done by ECL
Western blot detection reagent (GE Healthcare) and autoradiography film (MIDSCI, St. Louis, MO).
Effect of Antibody Treatment on VTV Budding—ER containing [3H]TAG (450 g of protein) was incubated with same
amount of indicated antibody (figure legends) or preimmune
IgG for 1 h at 4 °C as described previously (43). The ER was
washed with cold 0.1 M sucrose in Hepes buffer to remove
unbound antibody. The ER pellet was resuspended in transport
buffer (30 mM Hepes, 250 mM sucrose, 2.5 mM MgOAc, 30 mM
KCl; pH 7.2) and used in an in vitro VTV budding assay.
Transfection with siRNA—Rat primary hepatocytes were
transfected with CideB siRNA (Silencer select predesigned
SiRNA, Life Technologies). The sequence of siRNA was 5⬘CAUGAGCUGCGAUUUUCAATT3⬘. Transfection was carried out
by Lipofectamine by following the method according to manufacturer’s protocol (Life Technologies).
Immunocytochemistry—Primary rat hepatocytes were plated
on 22-mm round coverslips coated with collagen type I (BD

VTV Formation Requires CideB

FIGURE 2. CideB is present in VTV but not in PTV or PCTV. Protein samples
of purified VTV, PTV, and PCTV (each sample containing 40 g of protein)
were separated by 12% SDS-PAGE, transblotted onto a nitrocellulose membrane, and probed with specific antibodies against the indicated proteins.
Proteins were detected using ECL reagents. The data are representative of
four independent experiments.

hepatic ER, Golgi, and cytosol contain CideB, which is consistent with previous studies (21). However, CideB was found to be
the least in cytosolic fraction (Fig. 1A). Interestingly, we
observed that CideB is concentrated in VTV fractions as compared with their parent membrane, hepatic ER (Fig. 1A).
To illustrate the localization of CideB to the VTVs morphologically, we carried out immunogold labeling of CideB on the
VTVs and probed the results by electron microscopy using the
negative staining technique. As shown in Fig. 1B (panel II),
CideB is localized on the surface of the VTVs as established by
immunogold labeling. By contrast, control experiments using
preimmune IgG displayed no immunogold labeling (Fig. 1B,
panel I). Together, these biochemical and morphological data
strongly suggest that CideB is not only present on the surface of
the VTV but is concentrated in the VTVs.
CideB Is Not Present in ER-derived PTV and PCTV—Our
next aim was to find out whether CideB is present in other
ER-derived vesicles such as PTVs, which contain nascent secretory proteins, and PCTVs, which transport nascent lipoproteins of intestinal origin, the pre-chylomicrons (41, 42). We
isolated and purified these vesicles as discussed previously (53).
Our data reveal that CideB is not present in either PTV or
PCTV (Fig. 2); however, we observed a strong band of CideB in
the VTV fractions (Fig. 2), indicating that CideB is present in
VTVs only but not in other ER-derived vesicles. When we
probed for PTV marker protein, albumin (a hepatic secretory
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FIGURE 1. CideB concentrates in VTV. A, protein samples of purified fractions of ER, VTV, Golgi, and cytosol (each sample contains 35 g of protein)
were separated by 12% SDS-PAGE (except for apoB100; a 4 –20% gel was
utilized), transblotted onto a nitrocellulose membrane, and probed with specific antibodies against the indicated proteins. ECL reagents were used to
detect proteins. The data are representative of three independent experiments. B, visualization of CideB localization on VTVs by immunoelectron
microscopy using the negative staining. Freshly prepared VTVs were
adsorbed on Formvar/carbon-coated nickel grids, incubated with either antirabbit preimmune IgG (panel I) or rabbit polyclonal anti-CideB (panel II) antibodies, and probed with anti-rabbit IgG conjugated with 15-nm gold particles. Bar ⫽ 100 nm.

protein), we found a strong band of albumin in the PTV fraction. In addition, we immunoblotted for VAMP7, which is an
endosomal or post-Golgi protein but uniquely present in ERderived PCTVs (46). As expected, VAMP7 is enriched in the
PCTV fraction (Fig. 2); however, both VTV and PTV do not
have identifiable VAMP7 (Fig. 2), which is consistent with previous studies (21). Taken together, these data suggest that
CideB is specifically present in the VTVs.
CideB Interacts with apoB100 but Not with Albumin—Because both PTV and VTV are budding off the same ER at the
same time and CideB is not present in the PTV but is enriched
in VTV, we questioned whether it interacts with albumin (PTV
cargo protein) and apoB100 (a VTV cargo protein) at the ER
level. To address this issue, we carried out co-immunoprecipitation experiments utilizing ER membranes solubilized in 2%
Triton X-100 and specific CideB antibodies. Our results demonstrate that CideB co-immunoprecipitates apoB100 but not
albumin; however, albumin is present in the ER (Fig. 3A). These
findings suggest that CideB specifically interacts with VTV
cargo protein but not with PTV cargo, indicating its potential
role in VLDL transport from the ER to the Golgi.
To substantiate our observations pertaining to CideBapoB100 interaction at the ER level, we sought to provide additional morphological evidence using confocal microscopy. We
used a double-labeled immunofluorescence technique. As can
be seen in Fig. 3B, CideB co-localizes with apoB100. The middle
panel of Fig. 3B clearly shows the co-localization of apoB100
with CideB in the characteristic reticular structure of the ER.
Interestingly, we observed punctate co-staining most likely in
VTVs because this is characteristic staining of the ER-derived
vesicles (Fig. 3B, middle panel, arrowheads). To show that this
interaction occurs at the ER level, we used an ER marker, calnexin. The data presented in the lower panels of Fig. 3B indicate
that CideB co-localizes with calnexin. Together, these data confirm that the interaction between CideB and apoB100 is specific
and occurs at the level of the ER.
CideB Interacts with COPII Components—Because the VTV
originates from hepatic ER membrane in a COPII-dependent
fashion and CideB is specifically present in the VTV, it is likely
that CideB may interact with VTV coat proteins i.e. COPII proteins. Another reason for this assumption is that VTVs are

VTV Formation Requires CideB

FIGURE 3. CideB interacts with apoB100 but not with albumin. A, ER (250
g of protein) were solubilized in 2% (v/v) Triton X-100 and incubated with
anti-goat CideB antibody (10 g) for 4 h at 4 °C. Anti-goat IgGs bound to
agarose beads were added and incubated overnight at 4 °C. Immunocomplexes bound to agarose beads were isolated and washed 10 times with
ice-cold PBS to remove unbound proteins. Protein sample was separated by
SDS-PAGE (8 –16% gel) and probed with anti-CideB, anti-apoB100, and antialbumin antibodies. IP, immunoprecipitation. B, CideB co-localizes with
apoB100 in hepatic ER. Primary hepatocytes were double-labeled with either
CideB (FITC, green) and apoB100 (Texas Red, red) (upper and middle panels) or
CideB (FITC, green) and calnexin, an ER marker (Texas Red, red) (lower panel). In
the middle panel, we used higher magnification and less saturation of both
channels. Arrowheads in the middle panel show punctate vesicular staining in
the VTVs. The nucleus is stained with DAPI (blue). Merged figures show co-localization of CideB with apoB100 and calnexin.

larger in size than the typical COPII-coated PTVs, suggesting
that the assembly of VTV coat may require additional protein(s) to form a larger/modified COPII cage. To find out
whether CideB interacts with COPII proteins, we performed
co-immunoprecipitation experiments. Because all five COPII
proteins (i.e. Sar1, Sec23, Sec24, Sec13, and Sec31) are cytosolic,
we used hepatic cytosol anti-CideB antibodies in our co-immunoprecipitation assays.
To have high confidence in our results, we reprobed the same
membrane with different antibodies against each of the COPII
proteins. The immunoblotting data presented in Fig. 4 suggest
that CideB strongly interacts with Sar1 and Sec24; however, its
binding with Sec23 was minimal. Also, we did not observe a
strong signal for CideB interaction with Sec13 and Sec31 (Fig.
4). These data suggest that CideB interacts with select COPII
components (Sar1 and Sec24). Interaction between CideB and
Sec24 indicates that these two proteins form a heterodimer,
which in turn facilitates the assembly of an intricate COPII coat
necessary for VTV formation.
Blockade of CideB Reduces VTV Formation—That CideB is
specifically present in ER-derived VTVs and its interaction with
VTV cargo and VTV coat proteins raise the possibility of its
active involvement in the process of VTV biogenesis, and thus,
FEBRUARY 15, 2013 • VOLUME 288 • NUMBER 7

ER exit of nascent VLDL particles. To determine whether
CideB has some role in VTV budding from hepatic ER, we first
decided to examine the effect of blocking CideB using specific
antibodies on VTV budding. To accomplish this, we performed
an in vitro VTV budding assay that we have standardized previously (21). To block CideB on the ER, [3H]TAG-containing
hepatic ER membranes were preincubated at 4 °C with an equal
amount of either control IgG or anti-CideB antibodies. After
antibody treatment, excess antibodies were removed by washing. Because cytosol also contains a small amount of CideB, we
treated cytosol with anti-CideB antibodies or the preimmune
IgGs (control) bound to agarose beads prior to the budding
assay, and the excess antibodies were removed. Anti-CideB
antibody-treated ER membranes and cytosol were used in the
VTV budding assay (see “Experimental Procedures”). As presented in Fig. 5A, the treatment of hepatic ER with anti-CideB
antibodies significantly inhibited VTV generation. However,
IgG treatment did not have any effect on VTV budding activity
(Fig. 5A). These results show that CideB blockade results in
reduced VTV formation, suggesting an active role of CideB in
VTV biogenesis.
It is, however, possible that antibody treatment results in
nonspecific inhibition of the VTV budding process due to a
number of factors. To rule out the possibility of nonspecific
inhibition, we treated the ER and cytosol with a variety of antibodies against proteins that are known to be present on hepatic
ER and involved in ER-to-Golgi transport of proteins and lipoproteins. We used antibodies against syntaxin5, rbet1, ykt6, and
membrin, which have been well characterized to be present on
hepatic ER (21). We followed exactly the same protocol of antibody treatment as we used for CideB antibody treatment. Our
data reveal that the treatment with each of these antibodies did
not have any effect on VTV formation (Fig. 5B), suggesting that
the blocking effect of CideB on VTV generation was specific.
Moreover, we treated hepatic ER with VAMP7, which is
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 4. CideB interacts with COPII components. Rat hepatic cytosol (150
g of protein) was incubated with anti-goat CideB antibody bound to agarose beads at 4 °C overnight. Immunocomplexes bound to agarose beads
were isolated and washed thoroughly. The proteins were separated by SDSPAGE (5–15%) and probed with antibodies against the indicated proteins.
A single membrane was used, which was sequentially probed with the
indicated antibodies after washing. Protein detection was carried out
using ECL reagents. The results are representative of four experiments. IP,
immunoprecipitation.
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required for the generation of PCTVs from small intestinal ER
(46). As shown in Fig. 5B, there was no decrease in VTV budding as compared with control when VAMP7 antibodies were
used. To rule out the possibility of steric hindrance caused by
CideB antibody binding on the ER surface, we boiled these antibodies and used them in our budding assay. As expected, boiled
CideB antibodies did not inhibit VTV formation (Fig. 5A).
Because both Sar1 and Sec24 interact with CideB and apoB100,
it is possible that this interaction triggers the process of VTV
formation. To test this speculation, we decided to immunodeplete hepatic cytosol with specific antibodies against Sar1 and
Sec24 as we have done successfully previously (57). Also, we
washed our ER membranes with urea to remove peripheral Sar1
and Sec24 as we have done in the past (21). As can be seen in Fig.
5C, the Sar1- and Sec24-depleted system did not support the
formation of the VTV, which is consistent with published studies (56, 57). Taken together, these data strongly suggest that
CideB plays an important role in the biogenesis of the VTV.
Silencing of CideB Abrogates VTV Biogenesis—In an attempt
to provide more concrete evidence that CideB is crucial for the
genesis of the VTV, we sought to knock down CideB in primary
rat hepatocytes. We decided to use siRNA with Lipofectamine
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because this approach has been used successfully in primary rat
hepatocytes (58). After transfection, the level of CideB knockdown was ascertained in whole cell lysate, ER, and cytosol from
hepatocytes. As shown in Fig. 6A, 50 nM concentration of CideB
siRNA significantly decreased CideB protein levels as compared with control siRNA in rat primary hepatocytes, whereas
there was no effect on the expression of ␤-actin (Fig. 6A). Next,
we isolated the ER and the cytosol from these hepatocytes and
examined the presence of CideB using Western blotting. Fig. 6B
shows that the ER, isolated from CideB siRNA-treated hepatocytes, contains significantly low level of CideB, whereas there is
no effect on calnexin, an ER resident protein. Similarly, a
reduced level of CideB protein was found in cytosol prepared
from CideB knockdown hepatocytes, whereas there was no
effect on ␤-actin level in the same cytosol (Fig. 6C). Treatment
of control siRNA had no effect on the expression of CideB in
whole cell lysate, ER, or cytosol of hepatocytes (Fig. 6, A–C).
To find out the effect of knocking down CideB on VTV formation process, we carried out an in vitro VTV budding assay.
As we expected, VTV budding activity was significantly
decreased when CideB was knocked down as shown in Fig. 6D.
In contrast, there was no effect on VTV formation when control
siRNA was used (Fig. 6D). These data strongly suggest a functional role for CideB in VTV budding.

DISCUSSION
Increased secretion of very low density lipoproteins from the
liver is associated with hyperlipidemia, which is a major risk
factor for the development of various cardiovascular diseases.
The assembly of VLDL occurs in the ER lumen, and this step is
mediated by microsomal triglyceride transfer protein, which
possesses binding sites for both apoB100 and triglycerides (4,
5). After their biogenesis in the ER, newly synthesized VLDL
VOLUME 288 • NUMBER 7 • FEBRUARY 15, 2013

Downloaded from http://www.jbc.org/ at UCF Health Sciences Library on March 21, 2019

FIGURE 5. The effects of CideB blockade on VTV formation. VTV budding
assays were performed in which hepatic ER containing [3H]TAG was incubated with or without rat hepatic cytosol in the presence of an ATP-regenerating system. After incubation, the reaction mixture was resolved on a continuous sucrose density gradient, and fractions (0.5 ml) were collected. The
[3H]TAG dpm values in all fractions (500 l) were measured. A, prior to budding assay, the ER containing [3H]TAG was incubated at 4 °C for 2 h with
preimmune IgG, anti-CideB, or boiled anti-CideB antibodies, and antibodies
in each case were removed by washing. Cytosol was pretreated at 4 °C for 2 h
with preimmune IgG, anti-CideB, or boiled anti-CideB antibodies bound to
agarose beads, and the antibodies were removed by centrifugation. Results
are mean ⫾ S.D. (n ⫽ 4). Bars labeled with different symbols show p ⬍ 0.01
using one-way ANOVA. No cyto, absence of cytosol. B, the ER containing
[3H]TAG and the hepatic cytosol similar to panel A were treated prior to performing budding assays, with the indicated antibodies. Data are mean ⫾ S.D.
(n ⫽ 4). Bars labeled with different symbols are p ⬍ 0.005 using one-way
ANOVA. C, ER containing [3H]TAG and hepatic cytosol were pretreated with
the indicated antibodies and used in VTV budding assays as described above.
For details, see “Experimental Procedures.” Values are mean ⫾ S.D. (n ⫽ 4).
Bars labeled with different symbols have p ⬍ 0.001 using one-way ANOVA.

FIGURE 6. Knockdown of CideB in primary hepatocytes abrogates VTV
formation. Primary hepatocytes were transfected with either CideB siRNA
(5⬘CAUGAGCUGCGAUUUUCAATT3⬘) or control siRNA (Silencer select siRNA,
Ambion). ER containing [3H]TAG and cytosol were prepared and purified from
both sets of hepatocytes as described under “Experimental Procedures.”
A, protein samples of whole cell lysate (WCL). siCideB, CideB siRNA; siControl,
control siRNA. B, hepatic ER membranes. C, cytosol prepared from untreated
primary hepatocytes or treated with either CideB siRNA (siCideB) or control
siRNA (siControl) was probed with specific anti-CideB, anti-␤-actin, or anticalnexin antibodies. D, VTV budding assays were performed using ER containing [3H]TAG and cytosol, which were isolated from primary hepatocytes
treated with either CideB siRNA (siCideB) or control siRNA (siControl). As a
negative control, ER containing [3H]TAG isolated from untreated hepatocytes
was incubated in the absence of cytosol (No cyto). Results are mean ⫾ S.D.
(n ⫽ 4). Bars labeled with different symbols depict p ⬍ 0.001 using one-way
ANOVA.

VTV Formation Requires CideB

FEBRUARY 15, 2013 • VOLUME 288 • NUMBER 7

Does CideB interact with other secretory proteins and facilitate their ER exit? Co-immunoprecipitation analysis suggested
that CideB does not associate with liver secretory protein, albumin, which raises another important question whether the classical COPII-coated PTVs contain CideB or not. Because a number of previous studies have revealed that albumin utilizes
COPII-coated PTVs for its transport to the Golgi (15, 21), we
speculated that CideB might not be present in PTVs. The data
presented in this study demonstrate that PTVs indeed do not
contain CideB, suggesting that typical secretory cargo proteins
do not require proteins in addition to COPII components,
which is consistent with previous unambiguous findings suggesting that COPII proteins are sufficient to recruit nascent
proteins and generate PTVs from the ER membranes (22–31,
59). In contrast, it has been shown that special secretory cargo
proteins control the formation and the size of ER-derived PTVs
(39). Using a temperature-sensitive form of vesicular stomatitis
viral glycoprotein (VSV-Gts), Aridor et al. (60) showed that the
generation of PTVs from the ER membranes could be controlled by biosynthetic cargoes. The ability of secretory cargo
proteins to modulate the size of ER-derived vesicles has been
demonstrated by many groups (39, 61, 62). Recently, it has been
shown that ubiquitination of Sec31 by ubiquitin ligase CUL3KLHL12 regulates the size of the COPII coat (62). However,
several studies suggest the requirement of additional protein(s)
to form assorted COPII coats that lead to the generation of
larger ER-derived vesicles (39). The formation of pre-chylomicron transport vesicle requires four proteins in addition to
COPII proteins (43). Moreover, Shimoni et al. (39) showed that
the transport of plasma membrane ATPase from the ER to
Golgi requires Lst1 protein, which substitutes for Sec24 and
forms the heterodimer with Sec23, leading to plasma membrane ATPase selection into PTVs. Interestingly, these vesicles
were found to be larger than typical COPII-coated PTVs, supporting the thesis that cargo can influence the size of the vesicle.
These observations support our findings that VLDL regulates
the formation and size of specialized ER-derived VTVs.
The specific nature of the interaction between CideB and
apoB100 raises the possibility that CideB plays a crucial role in
VLDL sorting and the VTV biogenesis. Because previous published data suggested that VTVs do not carry albumin to the
Golgi (15, 21), it is likely that CideB functions as VLDL-selecting protein for the VTV. However, the absence of CideB in the
PTV and its interaction with COPII components support the
thesis that it facilitates the process of VTV formation. Fig. 7
summarizes a novel role of CideB in VTV biogenesis. The
potential role of CideB in VLDL selection as well as VTV formation is consistent with other studies in which Lst1 has been
shown to mediate the selection of specific secretory cargo and
the formation of larger ER-derived vesicles (39, 40).
Interaction of CideB with apoB100, Sar1, and Sec24 and its
presence in the VTV but not in other ER-derived vesicles (e.g.
PTV or PCTV) indicated that it might play a functional role
specifically in VTV generation. The data presented in this study
clearly demonstrate that both blocking CideB with specific
antibodies and CideB silencing using an siRNA approach significantly reduced the generation of the VTV, confirming its
functional role in VTV genesis. Unlike Sar1, a COPII compoJOURNAL OF BIOLOGICAL CHEMISTRY
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particles are exported to the Golgi, and this step determines the
rate of VLDL secretion from the liver. The transport of nascent
VLDL particles from the ER to the Golgi is mediated by specialized vesicles, the VTVs (10, 21). Our previous studies have
shown that the VTVs are different from the classical ER-derived COPII-coated PTVs that carry nascent proteins to the
Golgi (21). Despite their distinct cargoes, size, and protein compositions, both VTVs and PTVs utilize the COPII system for
their biogenesis (21). This indicates that the formation of the
VTVs requires other protein(s) in addition to the COPII
machinery. Taking these observations into account, we reasoned that the additional protein(s) that interacts specifically
with VLDL core protein (apoB100) forms an intricate COPII
complex, which facilitates the formation of the VTV from the
ER membranes. In this study, we tested our hypothesis and
provide the evidence that supports the involvement of an
additional protein, CideB, in VTV biogenesis. We found that
CideB interacts with VLDL protein (apoB100) and COPII
components.
Our recent study describing the VTV proteome suggested
the presence of a small Mr protein, CideB, in VTVs (48). In this
study, using biochemical methods, we confirmed that the VTVs
contain CideB. CideB has been shown to be present in ER,
Golgi, and lipid droplets. However, the presence of CideB in
ER-derived VTV is of particular interest because: (i) the VTV
exports nascent VLDL to the Golgi lumen; (ii) VLDL gets further lipidated in the Golgi; and (iii) CideB has been recently
shown to promote VLDL lipidation and maturation in the Golgi
lumen (50). Together, these observations led us to postulate
that CideB might have an unidentified role in VLDL export
from the ER to the Golgi.
The role of CideB in intracellular transport processes has not
been reported previously; however, a number of findings
related to CideB are consistent with the novel role proposed in
this study. For example, the liver of CideB knock-out mice has
been shown to secret reduced amounts of triglycerides (51).
Moreover, knockdown or complete ablation of CideB leads to
the secretion of triglyceride-poor VLDL particles from hepatocytes (49); in other words, CideB plays an important role in
VLDL delivery to the Golgi where VLDL undergoes additional
lipidation.
Although COPII proteins are sufficient to form vesicles from
the ER membranes, they interact with other proteins to make
specific COPII coats for distinct cargoes (23, 39 – 43). We contemplated the feasibility that CideB may interact with COPII
components of the VTV to form a specialized larger COPII cage
because CideB is present in COPII-coated VTVs, which are
larger in their size than standard PTVs. Our results clearly indicate that CideB interacts with COPII components, Sar1 and
Sec24. Binding of CideB with Sec24 is especially significant
because the resulting CideB-Sec24 heterodimer might be
involved in the formation of larger ER-derived vesicles that can
accommodate VLDL-sized particles, which is consistent with
data reported previously (39). Moreover, the presence of Sec23
in the VTV (21) raises the possibility that Sec24 forms two
heterodimers, CideB/Sec24 and Sec23/Sec24, to facilitate the
biogenesis of the VTV, and this supposition is consistent with
other studies (39).
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6.

7.

8.

nent that initiates VTV budding from hepatic ER membranes,
knockdown of CideB is not lethal. Primary hepatocytes lacking
CideB (hepatocytes isolated from CideB-null mice) continued
to secrete VLDL particles; however, these particles were found
to be smaller in size (49). Because CideB has been proposed to
be a multifunctional protein, which is involved in various stages
of VLDL lipidation in the ER as well as in the Golgi (49, 50),
knockdown of CideB from hepatocytes would lead to incomplete VLDL lipidation in both the ER and the Golgi. Under these
circumstances, immature VLDLs (smaller than normal VLDL
particles) would not require larger ER-derived vesicles; instead,
they can be transported to the Golgi in conventional COPIIcoated PTVs. However under normal conditions, a larger vesicle (i.e. VTV) is required for exporting VLDL to the Golgi, and
CideB plays an essential role in VTV biogenesis (Fig. 7).
In the present study, we have identified a new physiological
role for CideB as we demonstrated that CideB facilitates the
formation of ER-derived large vesicles. Using an siRNA
approach, we were able to demonstrate that the knockdown of
CideB significantly reduced the VTV generation. Our co-immunoprecipitation data show that CideB interacts with the
COPII components that might be necessary to build a larger
COPII cage and thus for the formation of VTV. We suggest that
the interaction between CideB and apoB100 (a VTV cargo protein) triggers the process of VTV formation. These findings
suggest that the size and the type of cargo regulate the assembly
of assorted coat complexes, leading to the genesis of vesicles of
various sizes.
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